The goal of gene therapy for patients with hemophilia A is to safely impart long-term stable factor VIII expression that predictably ameliorates bleeding with the use of the lowest possible vector ...
TUCKER, Ga. & ROCKVILLE, Md.--(BUSINESS WIRE)--Expression Therapeutics LLC, a biotechnology company developing high expression factor VIII technologies, together with ABL, Inc., a biomedical contract ...
Northwestern Medicine scientists have discovered how a specific transcription factor promotes genetic reprogramming and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback